TKPYY : Summary for TAKEDA PHARMACEUTI SPON ADR EA - Yahoo Finance

U.S. Markets closed

Takeda Pharmaceutical Company Limited (TKPYY)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
24.83+0.85 (+3.54%)
At close: 3:59PM EDT
People also watch
ALPMYESALYDSNKYTKPHFSVNDY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close23.98
Open24.08
Bid0.00 x
Ask0.00 x
Day's Range24.00 - 25.28
52 Week Range19.96 - 25.28
Volume49,367
Avg. Volume38,073
Market Cap37.79B
Beta0.41
PE Ratio (TTM)32.69
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.78 (3.31%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • InPlay from Briefing.com
    Briefing.com13 hours ago

    InPlay from Briefing.com

    InPlay from Briefing.com

  • Reuters2 days ago

    U.S. FDA approves Takeda's lung cancer drug as 2nd-line treatment

    Japan's Takeda Pharmaceutical Co Ltd said on Friday that the U.S. Food and Drug Administration approved its lung cancer drug, almost three months after the company acquired the drug's developer, Ariad Pharmaceuticals Inc. The drug, Alunbrig, is approved as a second-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer, who have progressed on or are intolerant to Pfizer's crizotinib, the standard initial treatment for the disease. Alunbrig was approved under the FDA's accelerated approval program, which allows for quicker approval of drugs that fill an unmet medical need.

  • PR Newswire3 days ago

    Takeda and Harrington Discovery Institute at University Hospitals Announce a Collaboration to Advance the Development of Rare Disease Therapeutics

    OSAKA, Japan and CLEVELAND, April 27, 2017 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE:4502), and Harrington Discovery Institute at University Hospitals in Cleveland, Ohio have announced a multi-year collaboration to accelerate breakthrough therapeutic discoveries in rare diseases. A first of a kind partnership for Harrington Discovery Institute with a major pharmaceutical company, this collaboration with Takeda will build on Harrington Discovery Institute's established operating model to create a new program specifically for the advancement of medicines for rare diseases.